The Global Health Body Raises Alert Over Acute Lack of Weight-Loss Medications

Fewer than 10% of individuals eligible to benefit from obesity jabs such as Wegovy can access them, states the global health agency as it releases its first recommendations on the drugs.

Given in excess of 1,000,000,000 people worldwide currently obese, it is urging more widespread and fairer availability to this class of drugs.

According to forecasts, more than two billion will be living with obesity by 2030 without intervention.

"Our latest guidance affirms that obesity is a chronic disease that can be managed with holistic and continuous support," remarked WHO director-general Tedros Adhanom Ghebreyesus.

Significant expense, insufficient output, and logistical bottlenecks are significant barriers to widespread access to the injections that can help people shift significant weight, notes the agency.

Skinny Jab Scarcity

Even under the present best projected scenario, the manufacturing of these medications might only reach around 100 million people – under 10% of those who need them, according to the WHO.

The advice encourages governments and firms to expand access, through measures including voluntary licensing.

Exclusive production rights on a key compound – the main ingredient of the drug Wegovy – is scheduled to end in a number of nations in 2026.

How Weight-Loss Injections Operate

These medications imitate a natural hormone to delay gastric emptying, suppress the appetite and boost feelings of fullness so users reduce food intake.

People commonly see weight reduction in the initial weeks of beginning the regular doses.

Evidence suggests patients may regain a significant portion a year later of halting the treatment, because their typical appetite return.

Being above a healthy weight elevates your chance for contracting health problems, including diabetes, heart disease, brain attack, and certain cancers.

Excess weight concerns people in every country and was responsible for over three and a half million deaths worldwide in 2024, according to the health agency.